{"schema":"hottub-news/story/v1","story":"st_ntjv2rrwywoc4k4dd7yq","title":"Zealand Pharma-aktien falder efter nye forsøgsdata","title_en":"Zealand Pharma shares fall after new trial data","outlets":4,"brief":null,"page":"https://hottub.news/stories/zealand-pharma-dives-into-new-trial-data-ntjv2rrwyw","count":4,"items":[{"id":"n_3wkdjnqiu3ors3zgwlna","seq":1094682,"kind":"article","title":"Zealand Pharma-aktien falder efter nye forsøgsdata","title_en":"Zealand Pharma shares fall after new trial data","url":"https://www.berlingske.dk/business/zealand-pharma-aktien-falder-efter-nye-forsoegsdata?referrer=RSS","summary":"Zealand Pharma-aktien handles 8,5 procent lavere efter nye fase 3-resultater med vægttabsmidlet survodutid.","published":"2026-10-01T08:45:45Z","seen":"2026-10-01T09:01:04Z","lang":"da","country":"DK","source":{"id":"kite-berlingske-dk-a0a3d7","name":"berlingske.dk","domain":"berlingske.dk","outlet":{"wikidata":"Q59055","name":"Berlingske","type":"newspaper","country":"DK","designations":["daily newspaper","newspaper","weekly newspaper"]}},"via":"kite-berlingske-dk-a0a3d7","topics":["business"],"entities":[{"id":"Q18552286","name":"Zealand Pharma","type":"org"}],"image":"https://akamai-aptoma-production.bmcdn.dk/users/berlingske/images/163178904.webp?accessToken=da4e45007a53dbad7f3e0fe3a7ca6741a6530e9d5fcd52c37e96cdb7d459d564&t[quality]=70&t[strip]=true","story":"st_ntjv2rrwywoc4k4dd7yq","category":"health","category_p":0.46000000834465027,"category2":"economy-business","sentiment":"negative","tone":-0.7900000214576721,"political":0.07000000029802322},{"id":"n_v2xd5oc3obhm42mcveca","seq":1083585,"kind":"article","title":"Zealand Pharma-aktien falder efter nye forsøgsdata","title_en":"Zealand Pharma stock falls after new trial data","url":"https://www.bt.dk/erhverv/zealand-pharma-aktien-falder-efter-nye-forsoegsdata?referrer=RSS","summary":"Zealand Pharma-aktien handles 8,5 procent lavere efter nye fase 3-resultater med vægttabsmidlet survodutid.","published":"2026-10-01T08:08:46Z","seen":"2026-10-01T08:20:21Z","lang":"da","country":"DK","source":{"id":"kite-bt-dk-3131ee","name":"bt.dk","domain":"bt.dk","outlet":{"wikidata":"Q327821","name":"B.T.","type":"newspaper","designations":["daily newspaper"]}},"via":"kite-bt-dk-3131ee","topics":["erhverv","nyheder"],"entities":[{"id":"Q18552286","name":"Zealand Pharma","type":"org"}],"story":"st_ntjv2rrwywoc4k4dd7yq","category":"health","category_p":0.46000000834465027,"category2":"economy-business","sentiment":"negative","tone":-0.7900000214576721,"political":0.07000000029802322},{"id":"n_2rq7jl4ukc5bqp2274ea","seq":1082069,"kind":"article","title":"Zealand Pharma-aktien falder efter nye forsøgsdata","title_en":"Zealand Pharma stock falls after new trial data","url":"https://www.kristeligt-dagblad.dk/zealand-pharma-aktien-falder-efter-nye-forsoegsdata","summary":"<p>Biotekselskabet Zealand Pharma falder torsdag morgen med 8,5 procent på fondsbørsen, efter at partneren Boehringer Ingelheim har offentliggjort nye forsøgsresultater.</p><p>Det drejer sig om vægttabsmidlet survodutid, som har været igennem et såkaldt fase 3-studie.</p><p>Personer med type 2-diabetes tabte sig 13,1 procent efter 76 ugers behandling med stoffet.</p><p>Det er 10,0 procentpoint mere end kontrolgruppen, der fik placebo i stedet for survodutid.</p><p>Derudover…","published":"2026-10-01T08:08:35Z","seen":"2026-10-01T08:13:10Z","lang":"da","country":"DK","source":{"id":"kite-kristeligt-dagblad-dk-2f056c","name":"kristeligt-dagblad.dk","domain":"kristeligt-dagblad.dk","outlet":{"wikidata":"Q1433145","name":"Kristeligt Dagblad","type":"newspaper","country":"DK","designations":["newspaper"]}},"via":"kite-kristeligt-dagblad-dk-2f056c","entities":[{"id":"Q18552286","name":"Zealand Pharma","type":"org"}],"story":"st_ntjv2rrwywoc4k4dd7yq","category":"health","category_p":0.46000000834465027,"category2":"economy-business","sentiment":"negative","tone":-0.7900000214576721,"political":0.07000000029802322},{"id":"n_ntjv2rrwywoc4k4dd7yq","seq":1094891,"kind":"article","title":"Zealand Pharma dykker stort efter nye forsøgsdata","title_en":"Zealand Pharma dives into new trial data","url":"https://borsen.dk/nyheder/virksomheder/zealand-pharma-dykker-stort-efter-nye-forsogsdata","summary":"Zealand Pharma er i frit fald torsdag, efter at partneren Boehringer Ingelheim har fremlagt nye data med midlet survodutid fra et fase 3-studie. Aktien står kl. 10.08 til 241,00 kr., hvilket svarer til et kursfald på 11,1 pct.","published":"2026-10-01T07:56:14Z","seen":"2026-10-01T09:07:49Z","lang":"da","country":"DK","source":{"id":"kite-borsen-dk-ead9a0","name":"borsen.dk","domain":"borsen.dk","outlet":{"wikidata":"Q5208470","name":"Dagbladet Børsen","type":"newspaper","country":"DK","designations":["daily newspaper","newspaper"]}},"via":"kite-borsen-dk-ead9a0","entities":[{"id":"Q18552286","name":"Zealand Pharma","type":"org"}],"image":"https://media.borsen.dk/brapi/size/1200/006d3e97-1f3b-4662-903f-4b8c022db54f-landscape/4098780-20261001081048/9f7275c65046368bea74ee1d8267207e25bd07d9601f199af1d460a0d7c41e5c.jpg","story":"st_ntjv2rrwywoc4k4dd7yq","category":"economy-business","category_p":0.5,"category2":"health","sentiment":"negative","tone":-0.75,"political":0.03999999910593033}]}